THE TAPE
IBRX · Biotechnology · $6.3B

ImmunityBio, Inc. Common Stock

$5.98▼ −0.66%
Last close
Relative strength
93RS
of 99, against every stock▼ -5 on the month
Cooling off
Unconfirmed
−39.1%
six months against Biotechnology
52-week range
−51.9%
from the high
$1.95$12.43
Setup
vcpplayed out
−27.8%
against the pivot at $8.28
No report date on the calendar.
Growth REALProof PENDING
Quarter to Sep 30, revenue +52% on a year ago
11/16 O 5.83 H 6.14 L 5.76 Vol 12.8M
Draw
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year

The four are not in order. That is a description of where the averages sit, not a view about what happens next.

RS93
vs pivot−27.78%
Tightening1.57×
Dry-up1.95×
Up/down vol-0.05
From high52%
failed pokeplayed out3 of 9checks
Previous breakout trailed out ▲ +86.84% in Jan
Cooling off
Support and resistance
Support below
None within the last 120 sessions
Resistance above
$6.77
+13.2% · tested 8× · last 5 sessions ago

Prices this stock has turned at three or more times in the last 120 sessions, with how many times. Where buyers and sellers showed up before, not a forecast, an entry or a stop.

The read

The base has run 3.6 weeks and fell 33% from its ceiling at its deepest. The pivot is $8.28, and the stock closed 27.8% below it. Its relative strength rating is 93.

Against its industry
UnconfirmedNone of the patterns above holds.
One month against its industry
-36.7%
Three months against its industry
-17.4%
Six months against its industry
-39.1%

Read against an equal-weighted index of Biotechnology, which is +22.6% against the S&P 500 over six months Partly aligned.

Peers
Same theme
No themes — common and fine.
Catalyst roadmap

Nothing dated in the next three months that we can ingest automatically.

How it moves on earnings

On average 11.7% either way across its last 8 reports.

Checking your subscription…

Close before the report day to close after it, so it holds whether the company reported before the open or after the close.

The business
Revenue
$182.6M
+52.3% year on year
Operating margin
-150.2%
Net margin
-607.8%
Free cash flow
$-296.7M
-4.7% of market cap
Price to sales
34.7×
Price to earnings
—
not meaningful on a loss

Twelve months to Sep 30, 2026, the four latest quarters in the company’s SEC filings, with the fiscal fourth quarter worked out from the annual report. Revenue growth is the latest quarter against the same quarter a year earlier.

The latest quarter, read by fixed rules · reported Nov 9
Key takeaway
Real growth, but execution and cash generation are not yet proven.
Revenue
$48.8M
-4.7% QoQ · +52.3% YoY
Gross margin
—
Net income
−$184.6M
Loss
Free cash flow
−$78.3M
Burning · 1q runway

What the numbers say

  • Good: Revenue +52.3% year over year, -4.7% on the quarter
  • Weak: Net loss $185M, narrower than $230M last quarter
  • Weak: Burning cash: operating cash flow -$75M, free cash flow -$78M, worse than -$70M last quarter · 1 quarter of cash at this burn
  • Weak: Growth externally funded: capex $3M against operating cash flow -$75M; share count +12.1% in a year
  • Good: Net cash $45M · cash $45M
Revenue by quarter
Free cash flow
Net income
shares +12.1% in a year · net cash $45.1M

What is not obvious

  • Weak: Stock compensation $9M added back against negative operating cash flow
Final read
Growth: REAL · Economic proof: PENDING
Key question: Can the growth turn into durable profit and cash after its costs and financing?
The next test is operating profit: net loss $185M, narrower than $230M last quarter.

From the company’s 10-Q and 10-K filings, by Market Desk’s rules. Every line, the takeaway and the final read are fixed rules on the filed numbers; nothing reads the press release, and none of it enters a screen or a rating. Every recent reporter.

Tracked funds

Held by 1 of 46 tracked funds at the end of Q3 2026.

Last quarter: 1 added, 1 sold out.

Checking your subscription…

From 13F filings, which show long stock only and arrive up to 45 days after the quarter. The broad quant funds are left out.

Flagged by the market sweep
GappedTape · 2026-11-13
-9.0%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
GappedTape · 2026-11-11
-5.1%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Closed below its 20- and 50-day on heavy volumeTape · 2026-11-10
below 20d & 50d on 3.2x volume at 7.11
No measurable effect: stocks behave like random ones over the next three sessions (1,780 cases over 60 nights).
GappedTape · 2026-11-10
-17.7%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Unusual volumeTape · 2026-11-10
4.6 sigma
After this signal, stocks have lagged random stocks by 0.1% over the next three sessions (6,474 cases over 55 nights). Against their own sector they have lagged by 0.4%.
GappedTape · 2026-11-07
+7.8%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
GappedTape · 2026-11-06
-10.3%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Moved 5%+ down on earningsTape · 2026-11-06
-10.3% on earnings 2026-11-05
No measurable effect: stocks behave like random ones over the next three sessions (665 cases over 44 nights).

From a separate overnight market sweep, not from the screens on this site. What it flagged, not what it means. The track record is the sweep's own, measured against random stocks over the last 90 days.

In the news
Insiders
Bought on the open market
0
Sold on the open market
8
$5,039,284 total

Sold: Simon Barry J., Cohen Cheryl, Selecky Christobel.

Not counted above: 9 filings for awards, option exercises, gifts or shares withheld to pay tax. Those follow a vesting schedule nobody chose the timing of, and counting them as selling is how that number gets misread.

Most recent filings
2026-10-05 Simon Barry J. · Directorsell25,000$268,760
2026-10-02 Cohen Cheryl · Directoroption exercise55,979$166,817
2026-10-02 Cohen Cheryl · Directorsell81,056$851,088
2026-07-02 Cohen Cheryl · Directoroption exercise55,979$166,817
2026-07-02 Cohen Cheryl · Directorsell131,210$1,246,941
2026-07-01 Selecky Christobel · Directoroption exercise35,064$104,491
2026-07-01 Selecky Christobel · Directoroption exercise124,414$371,998
2026-07-01 Selecky Christobel · Directorsell159,478$1,439,066

From SEC Form 4, filed within two business days of the trade. What was filed, not what it means.

What lines up

3 of 9 published checks currently line up. This is a count, not a probability — nothing on this site measures how often a setup works.

Relative strength of 80 or better
Above its 50-day line
Above its 200-day line
Averages fully stacked
Within 5% of its pivot
Range tightening through the base
Volume drying up through the base
More up-volume than down-volume
Within 15% of its 52-week high
What analysts expect
Strong buy1
Buy3
Hold0
Sell0
Strong sell0

These are analysts’ estimates, not ours, and not a projection this site endorses. They are published here because what the sell side expects is itself a fact about the market.

Checking your subscription…

Gamma concentration

No option open interest for this company. Most listed names have no options at all, and we only read chains for names carrying a dated event, so this is a normal reading rather than a fault.

X-ray

The most recent of 2 completed bases.

Checking your subscription…

A screening and market-analytics tool. Not investment advice. We are not a registered investment adviser. A stock on a screen matches a shape; that is not a prediction. Prices are end-of-day, not live.

What that means, in full
ImmunityBio, Inc. Common Stock (IBRX) — The Tape